Amid 'Substantial Doubt,' 23andMe Cuts 40% of Workers
The genetic testing company 23andMe hasn't been doing so hot lately, watching its share price plummet more than 70% this year, and CEO Anne Wojcicki has desperately been trying to right the ship. Now,
Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
In a prepared statement, 23andMe CEO and co-founder Anne Wojcicki said the company was “taking these difficult but necessary actions” as it focuses on “the long-term success of our core consumer business and research partnerships.” RELATED ...
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe cuts 40% of its workforce, discontinues all therapy programs
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies in development.
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival. The once-popular DNA-testing site will also halt work on therapies it was developing.
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
23andMe Cuts 40% of Workforce As Its Core Consumer DNA-Testing Business Struggles
Me announced on Monday it would cut approximately 40% of its workforce, impacting over 200 employees. The restructuring includes closing its drug development arm, ending trials for two advanced drug candidates,
23andMe is laying off 40% of its workforce right before the holiday season
Me is laying off 40% of its workforce right before the holiday season - The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach,
Hosted on MSN1d
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...
Rolling Out1d
23andMe cuts 40 percent of staff amid major business overhaul
In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe cuts 40% of staff in restructuring
Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...
Hosted on MSN1d
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable
Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream ...